Art

J-GLOBAL ID：201002271366670919   Reference number：10A0932093

Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays

慢性骨髄性白血病におけるキナーゼ阻害剤治療に反応する急速なクローンシフトが定量突然変異試験により見出される

Author (8)： YIN C. Cameron (Univ. Texas M.D. Anderson Cancer Center, Texas, USA) ,  CORTES Jorge (Univ. Texas M.D. Anderson Cancer Center, Texas, USA) ,  GALBINCEA John (Univ. Texas M.D. Anderson Cancer Center, Texas, USA) ,  REDDY Neelima (Univ. Texas M.D. Anderson Cancer Center, Texas, USA) ,  BREEDEN Megan (Univ. Texas M.D. Anderson Cancer Center, Texas, USA) ,  JABBOUR Elias (Univ. Texas M.D. Anderson Cancer Center, Texas, USA) ,  LUTHRA Rajyalakshmi (Univ. Texas M.D. Anderson Cancer Center, Texas, USA) ,  JONES Dan (Univ. Texas M.D. Anderson Cancer Center, Texas, USA)
Material： Cancer Science  (Cancer Sci)
Volume： 101  Issue： 9  Page： 2005-2010  Publication year： Sep. 2010 
JST Material Number： W1423A  ISSN： 1347-9032  Document type： Article
Article type： 原著論文  Country of issue： Australia (AUS)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： クローンシフト ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A0932093&from=J-GLOBAL&jstjournalNo=W1423A") }}

JST classification (2)： Treatment for tumors in general  (GE03031L) ,  Blood cell tumors(=neoplasms)  (GK04000M)

Substance index (1)： Imatinib

Reference (15)：

• CORTES, J. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007, 110, 4005-4011
• SOVERINI, S. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients : by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006, 12, 7374-7379
• JABBOUR, E. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006, 20, 1767-1773
• LAHAYE, T. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center : a 4.5-year follow-up. Cancer. 2005, 103, 1659-1669
• AL-ALI, HK. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J. 2004, 5, 55-60

Terms in the title (8)： 慢性骨髄性白血病 ,  キナーゼ阻害剤 ,  治療 ,  クローン ,  シフト ,  定量 ,  突然変異 ,  試験